Previous 10 | Next 10 |
– Preclinical data demonstrated PALI-2108 to be safe and well tolerated – PALI-2108 is orally delivered and colon activated allowing for local activity with low systemic exposure – Company advancing PALI-2108 for the treatment of moderate-to-severe ulcerative ...
Carlsbad, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that its abst...
2023-12-29 16:16:22 ET More on Palisade Bio Seeking Alpha’s Quant Rating on Palisade Bio Historical earnings data for Palisade Bio Financial information for Palisade Bio For further details see: Palisade Bio files to sell its shares
- Company’s co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding as part of previously announced grant from the US Crohn’s and Colitis Foundation - Lead program, PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) a...
Palisade Bio Inc. (PALI) is expected to report for Q3 2023
2023-11-10 08:12:11 ET More on Palisade Bio Palisade Bio drops 6%, names new chief medical officer Palisade stock rallies as high as 180% on IBD drug licensing deal Seeking Alpha’s Quant Rating on Palisade Bio Historical earnings data for Palisade Bio ...
– Transformational transaction jumpstarts development pipeline into high-value inflammatory bowel disease (IBD) market – Lead program, PALI-2108, oral prodrug therapy for the treatment of moderate-to-severe ulcerative colitis (UC) is anticipated to commen...
Live moderated webcast with J.D. Finley, Chief Executive Officer of Palisade Bio on Wednesday, October 25 th at 2:00 PM ET Carlsbad, CA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a biopharmaceutical company focused on developing novel ther...
Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has closed its previously announced registered direct offering with...
2023-09-11 09:15:17 ET More on Palisade Bio Financial information for Palisade Bio Palisade stock rallies as high as 180% on IBD drug licensing deal Palisade Bio fails in mid-stage trial for lead asset For further details see: Palisade Bio drops 6%, names...
News, Short Squeeze, Breakout and More Instantly...
Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides Composition o...
Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track to commence Ph...
Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel...